CompanyGraph
What stands out
- Valued far above the size of its business
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- ScaleRevenue is $16.46M, lower than 95% of all stocks globally
- PositionOperating margin is -244525.6%, lower than 95% of its Biotechnology peers (median -38%)
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
What stands out
- Valued far above the size of its business
Financials view
Market Capitalization
2.34BCNY349.41M · vs all stocks (USD)
Revenue (TTM)
110.27MCNY16.46M · vs all stocks (USD)
Profit Margin
-172.20%vs Biotechnology peers
Beta
0.2810xvs all stocks
52-Week Change
22.74%vs all stocks
Market Capitalization
2.34BCNY349.41M · vs all stocks (USD)
Enterprise Value
2.10BCNY314.12M · vs all stocks (USD)
Price to Sales (TTM)
19.69xvs Biotechnology peers
Price to Book (MRQ)
2.07xvs Biotechnology peers
Enterprise to Revenue
19.08xvs Biotechnology peers
Enterprise to EBITDA
-12.77xvs Biotechnology peers
Profit Margin
-172.20%vs Biotechnology peers
Return on Assets (TTM)
-8.47%vs Biotechnology peers
Return on Equity (TTM)
-16.61%vs Biotechnology peers
Revenue (TTM)
110.27MCNY16.46M · vs all stocks (USD)
Revenue per Share (TTM)
0.8940CNYUpdated Sep 22, 2026Quarterly Revenue Growth
-79.90%vs Biotechnology peers
Gross Profit (TTM)
45.70MCNY6.82M · vs all stocks (USD)
EBITDA (TTM)
-164.77MCNY-24.60M · vs all stocks (USD)
Net Income (TTM)
-189.88MCNY-28.34M · vs all stocks (USD)
Quarterly Earnings Growth (YoY)
-99.65%vs Biotechnology peers
Operating Cash Flow (TTM)
-116.27MCNY-17.36M · vs all stocks (USD)
Levered Free Cash Flow (TTM)
-116.53MCNY-17.39M · vs all stocks (USD)
Payout Ratio
0.00%vs Biotechnology peers
Revenue
112.88MCNYFY2025 · Dec 31, 2025Cost of Goods Sold
40.22MCNYFY2025 · Dec 31, 2025Gross Profit
72.67MCNYFY2025 · Dec 31, 2025Operating Income
-169.72MCNY-25.33M · vs all stocks (USD)
Pre-tax Income
-197.21MCNYFY2025 · Dec 31, 2025Income Tax Expense
-18.75MCNYFY2025 · Dec 31, 2025Net Income
-178.46MCNYFY2025 · Dec 31, 2025EBIT
-195.94MCNYFY2025 · Dec 31, 2025EBITDA (Income Statement)
-132.27MCNYFY2025 · Dec 31, 2025Research & Development
91.78MCNYFY2025 · Dec 31, 2025Selling, General & Administrative
100.95MCNYFY2025 · Dec 31, 2025Other Operating Expenses
4.63MCNYFY2025 · Dec 31, 2025Non-operating Interest Income
369.96KCNYFY2025 · Dec 31, 2025Non-operating Interest Expense
1.28MCNYFY2025 · Dec 31, 2025EPS (Basic)
-1.45CNYFY2025 · Dec 31, 2025EPS (Diluted)
-1.45CNYFY2025 · Dec 31, 2025Basic Shares Outstanding
123.08MSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
123.08MSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
-178.46MCNYFY2025 · Dec 31, 2025Preferred Stock Dividends
0.00CNYFY2025 · Dec 31, 2025Operating Cash Flow
-223.63MCNYFY2025 · Dec 31, 2025Free Cash Flow
-258.60MCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
84.19MCNYFY2025 · Dec 31, 2025Starting Profit (CF Statement)
-178.46MCNYFY2025 · Dec 31, 2025Other Non-cash Items
1.87MCNYFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
-29.72MCNYFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
-17.32MCNYFY2025 · Dec 31, 2025Capital Expenditures
-34.97MCNYFY2025 · Dec 31, 2025Sale of Investments
5.25MCNYFY2025 · Dec 31, 2025Other Investing Activity
163.60MCNYFY2025 · Dec 31, 2025Net Investing Cash Flow
133.88MCNYFY2025 · Dec 31, 2025Long-term Debt Issuance
103.00MCNYFY2025 · Dec 31, 2025Long-term Debt Payments
-52.60MCNYFY2025 · Dec 31, 2025Common Dividends Paid
-1.26MCNYFY2025 · Dec 31, 2025Net Financing Cash Flow
49.14MCNYFY2025 · Dec 31, 2025Shares Outstanding
123.20MSharesUpdated Sep 22, 2026Float Shares
36.48MSharesUpdated Sep 22, 2026% Held by Insiders
76.00%vs all stocks
% Held by Institutions
1.38%vs all stocks
Total Cash (MRQ)
190.43MCNY28.43M · vs all stocks (USD)
Total Cash per Share (MRQ)
1.55CNYUpdated Sep 22, 2026Total Debt (MRQ)
124.05MCNY18.52M · vs all stocks (USD)
Total Debt to Equity (MRQ)
0.1184xvs Biotechnology peers
Current Ratio (MRQ)
1.57xvs Biotechnology peers
Book Value per Share (MRQ)
8.51CNYUpdated Sep 22, 2026Total Assets
1.42BCNY211.76M · vs all stocks (USD)
Total Current Assets
355.66MCNYFY2025 · Dec 31, 2025Total Liabilities
319.50MCNYFY2025 · Dec 31, 2025Total Non-current Assets
1.06BCNYFY2025 · Dec 31, 2025Total Non-current Liabilities
77.84MCNYFY2025 · Dec 31, 2025Total Current Liabilities
241.66MCNYFY2025 · Dec 31, 2025Cash
84.19MCNYFY2025 · Dec 31, 2025Cash Equivalents
0.00CNYFY2025 · Dec 31, 2025Cash & Cash Equivalents
84.19MCNYFY2025 · Dec 31, 2025Other Short-term Investments
109.05MCNYFY2025 · Dec 31, 2025Accounts Receivable
139.74MCNYFY2025 · Dec 31, 2025Inventory
16.33MCNYFY2025 · Dec 31, 2025Accounts Payable
77.90MCNYFY2025 · Dec 31, 2025Short-term Debt
70.05MCNYFY2025 · Dec 31, 2025Long-term Debt
28.01MCNYFY2025 · Dec 31, 2025Other Non-current Liabilities
24.68MCNYFY2025 · Dec 31, 2025Common Stock (Book)
123.20MCNYFY2025 · Dec 31, 2025Retained Earnings
-166.72MCNYFY2025 · Dec 31, 2025Total Shareholders' Equity
1.10BCNY164.06M · vs all stocks (USD)
52-Week Low
12.50CNYUpdated Sep 22, 202652-Week High
31.20CNYUpdated Sep 22, 202652-Week Change
22.74%vs all stocks
Beta
0.2810xvs all stocks
50-Day MA
15.56CNYUpdated Sep 22, 2026200-Day MA
17.91CNYUpdated Sep 22, 2026Avg 10-Day Volume
2.31MSharesUpdated Sep 22, 2026Avg 30-Day Volume
2.50MSharesUpdated Sep 22, 2026Diluted EPS (TTM)
-1.54CNYUpdated Sep 22, 2026Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Peer Positioning
Operating margin is -244525.6%, lower than 95% of its Biotechnology peers (median -38%)Significant
Operating margin: -2,445.256Industry median: -0.38Industry P5: -43.63Peers compared: 260
Structural Tensions
Valued far above the size of its businessSignificant
Price-to-Sales: 19.69Revenue Growth YoY: -0.80
Financial Health
Altman Z-Score 3.95: safe zoneNotable
Altman Z-Score: 3.95
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Scale
Revenue is $16.46M, lower than 95% of all stocks globallySignificant
Revenue (USD): 16,459,961.104Global P5: 33,357,653.812
Companies that share the same coordination system — how they create, deliver, or capture value.
Shoulder Innovations, Inc.
Tier 1ProductionApproval-Gated PipelineRule
Emergent BioSolutions Inc.
Tier 1ProductionApproval-Gated PipelineRule
Cabaletta Bio Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Hainan Huluwa Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Surrozen, Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Enanta Pharmaceuticals Inc.
Tier 1ProductionApproval-Gated PipelineRule
Ocugen Inc.
Tier 1ProductionApproval-Gated PipelineRule
CapsoVision, Inc.
Tier 1ProductionApproval-Gated PipelineRuleSenseMaking
Zhejiang Zhenyuan Co., Ltd.
Tier 1ProductionApproval-Gated PipelineFlowRule
Jilin Jian Yisheng Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineFlowRule